Skip to content

Molecular mechanism and clinical detection of HER2 low expression subtype breast cancer

Molecular mechanism and clinical detection of HER2 low expression subtype breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101805
Enrollment
Unknown
Registered
2025-04-29
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

HRE2 non-expression group:None
HRE2 low expression group:None
HRE2 high expression group:None

Sponsors

Yuebei People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patient age 18-60 years; 2. Patients with breast cancer pathologically diagnosed according to Chinese CACA and CSCO guidelines, and the expression of HER2 immunohistochemistry is (-), if the expression of HER2 immunohistochemistry is , the expression of FISH is negative, it is regarded as low expression, if the expression of HER2 immunohistochemistry is , and the expression of FISH is positive, it is regarded as high expression; 3. The patient signs the informed consent form.

Exclusion criteria

Exclusion criteria: Patient has not signed an informed consent form.

Design outcomes

Primary

MeasureTime frame
HER2;

Countries

China

Contacts

Public ContactJiang Jinqun

Yuebei People’s Hospital

jjqiong1986@163.com+86 751 6913343

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026